Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Brain Injuries

ClinicalTrials.gov lists 2,874 trials for Brain Injuries or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 84.

MeSH D001930 Nervous System Diseases C10 C26
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 111 Phase 1/2 Phase 1/2 41 Phase 2 Phase 2 175 Phase 2/3 Phase 2/3 24 Phase 3 Phase 3 89 Phase 4 Phase 4 88 Not applicable Not applicable 1,421 Observational Observational 924 Phase 1 Phase 1 111 Phase 1/2 Phase 1/2 41 Phase 2 Phase 2 175 Phase 2/3 Phase 2/3 24 Phase 3 Phase 3 89 Phase 4 Phase 4 88 Not applicable Not applicable 1,421 Observational Observational 924

Trials per phase (log scale)

1 more section with rows

915 of the 2,874 trials are tagged with Brain Injuries itself; the rest are tagged with a narrower condition beneath it.

Get the Brain Injuries report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Brain Injuries trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 220

1991: 1 trials (Phase 3 1) 1992: 1 trials (Observational 1) 1993: 1 trials (Phase 3 1) 1996: 2 trials (Not applicable 1, Phase 2 1) 1997: 2 trials (Observational 1, Phase 2 1) 1998: 3 trials (Observational 2, Phase 3 1) 1999: 1 trials (Not applicable 1) 2000: 2 trials (Observational 1, Not applicable 1) 2001: 4 trials (Observational 2, Phase 3 1, Phase 1 1) 2002: 20 trials (Observational 2, Not applicable 3, Phase 4 6, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 4) 2003: 26 trials (Observational 7, Not applicable 6, Phase 4 4, Phase 3 2, Phase 2/3 3, Phase 2 4) 2004: 23 trials (Observational 8, Not applicable 8, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 2) 2005: 25 trials (Observational 8, Not applicable 9, Phase 4 2, Phase 3 1, Phase 2 4, Phase 1/2 1) 2006: 25 trials (Observational 7, Not applicable 7, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 1, Phase 1 4) 2007: 46 trials (Observational 20, Not applicable 11, Phase 4 5, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1 3) 2008: 60 trials (Observational 20, Not applicable 21, Phase 4 4, Phase 3 2, Phase 2/3 2, Phase 2 5, Phase 1/2 3, Phase 1 3) 2009: 57 trials (Observational 17, Not applicable 20, Phase 4 1, Phase 3 3, Phase 2 10, Phase 1/2 2, Phase 1 4) 2010: 73 trials (Observational 27, Not applicable 18, Phase 4 3, Phase 3 8, Phase 2 11, Phase 1/2 2, Phase 1 4) 2011: 93 trials (Observational 37, Not applicable 26, Phase 4 4, Phase 3 3, Phase 2/3 2, Phase 2 10, Phase 1/2 5, Phase 1 6) 2012: 83 trials (Observational 35, Not applicable 28, Phase 4 5, Phase 3 3, Phase 2 3, Phase 1/2 4, Phase 1 5) 2013: 118 trials (Observational 32, Not applicable 59, Phase 4 7, Phase 3 1, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 6) 2014: 130 trials (Observational 31, Not applicable 70, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 16, Phase 1/2 1, Phase 1 3) 2015: 133 trials (Observational 48, Not applicable 69, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 6, Phase 1 6) 2016: 163 trials (Observational 48, Not applicable 91, Phase 4 4, Phase 3 5, Phase 2 8, Phase 1/2 3, Phase 1 4) 2017: 152 trials (Observational 47, Not applicable 90, Phase 4 3, Phase 3 1, Phase 2 7, Phase 1/2 3, Phase 1 1) 2018: 168 trials (Observational 55, Not applicable 95, Phase 4 2, Phase 3 5, Phase 2 4, Phase 1/2 2, Phase 1 5) 2019: 166 trials (Observational 48, Not applicable 97, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 2) 2020: 153 trials (Observational 50, Not applicable 77, Phase 4 6, Phase 3 5, Phase 2 7, Phase 1/2 1, Phase 1 7) 2021: 220 trials (Observational 79, Not applicable 118, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 6) 2022: 151 trials (Observational 52, Not applicable 87, Phase 3 4, Phase 2 3, Phase 1/2 2, Phase 1 3) 2023: 184 trials (Observational 60, Not applicable 100, Phase 4 3, Phase 3 6, Phase 2 8, Phase 1 7) 2024: 194 trials (Observational 66, Not applicable 100, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 12, Phase 1/2 2, Phase 1 7) 2025: 194 trials (Observational 56, Not applicable 106, Phase 4 6, Phase 3 5, Phase 2/3 3, Phase 2 10, Phase 1/2 1, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 178
2025 194
2024 194
2023 184
2022 151
2021 220
2020 153
2019 166
2018 168
2017 152

Forecast of the full-year count, planned starts included, not rows of this table: about 190 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 281 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 1,624 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Brain Injuries trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 111
Phase 1/2 41
Phase 2 175
Phase 2/3 24
Phase 3 89
Phase 4 88
Not applicable 1,421
Observational 924
Expanded access 1

How many Brain Injuries trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 172
Recruiting 394
Enrolling by invitation 47
Active, not recruiting 77
Available 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Brain Injuries trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
VA Office of Research and Development 84

Which drugs are being tested for Brain Injuries? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DEXMEDETOMIDINE 13
METHYLPHENIDATE 9

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Hyperbaric Oxygen 22
Aerobic exercise 15
Treatment As Usual 13
somatropin AQ 12
type A botulinum toxin 11

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Brain Injuries trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 422 15
Increased intracranial hemorrhage on serial head CT 239 1
CNS 125 1
Shock 121 3
Acute Kidney Injury 118 1

Which publications cover Brain Injuries? (2,410)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages